| Angela Maureen Boyer, MS CCC-SLP | |
|
10313 Sw Denney Rd, Beaverton, OR 97008-6017 | |
| (971) 645-5679 | |
| Not Available |
| Full Name | Angela Maureen Boyer |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 10313 Sw Denney Rd, Beaverton, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1538425640 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 12692 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Angela Maureen Boyer, MS CCC-SLP 10313 Sw Denney Rd, Beaverton, OR 97008-6017 Ph: (971) 645-5679 | Angela Maureen Boyer, MS CCC-SLP 10313 Sw Denney Rd, Beaverton, OR 97008-6017 Ph: (971) 645-5679 |
News Archive
ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, has entered into definitive agreements with existing and new accredited investors to sell, in a registered direct offering, an aggregate of approximately 2.3 million shares of its common stock at a price of $2.55 per share for aggregate gross proceeds of $6.0 million.
As legal access to marijuana continues expanding across the U.S., more scientists are studying the effects of its active ingredient, tetrahydrocannabinol (THC), in teens, adults and pregnant women.
In the Jan. 11 online edition of Nature Genetics, they report the results of their two-stage genome-wide association study of patients with Alzheimer's disease. The research showed that women who inherited two copies of a variant in the PCDH11X gene, found on the X chromosome, are at considerably greater risk of developing Alzheimer's disease.
Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.
› Verified 8 days ago
Ryan Joseph Depauw, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1815 Nw 169th Pl Ste 3070, Beaverton, OR 97006 Phone: 971-249-2653 Fax: 503-747-4373 | |
Stephanie K. Crawford, M.S. CCC-SLP Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 1500 Nw Bethany Blvd, Beaverton, OR 97006 Phone: 503-346-0640 Fax: 503-346-8040 | |
Kate England, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 17185 Sw Watercrest Ct, Beaverton, OR 97006 Phone: 503-645-3898 | |
Mrs. Naomi J Beale, MS SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 14645 Sw Farmington Rd, Beaverton, OR 97007 Phone: 503-643-8626 | |
Sarah Lynn Kuhrts, MS, CCC, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4900 Sw Griffith Drive, Suite 157, Beaverton, OR 97005 Phone: 503-517-8555 Fax: 503-517-8556 | |
Rachel Prevost, MS, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 13200 Sw Butner Rd, Beaverton, OR 97005 Phone: 702-305-7842 | |
Mrs. Tatiana Virginia Ledoux, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8625 Sw Cascade Ave Ste 320, Beaverton, OR 97008 Phone: 877-755-8940 |